02:05 , Dec 2, 2017 |  BioCentury  |  Product Development

PAIRing up in Parkinson’s

A research partnership with the Parkinson’s Foundation helped Pfizer Inc. streamline a clinical program in Parkinson’s disease and identify outcomes to measure that are more in line with patients’ priorities. As a result of the...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Company News

Epic Pharma, Humanwell Healthcare Group, PuraCap Pharmaceutical LLC deal

Humanwell and PuraCap will acquire generic company Epic for $550 million. Epic’s assets include generics of cardiovascular drug amlodipine, marketed as Norvasc by Pfizer Inc. (NYSE:PFE, New York, N.Y.); depression drug citalopram, marketed as Celexa...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

NIH, Northwestern University, Parkinson Study Group, Michael J. Fox Foundation For Parkinson's Research neurology news

MJFF said NIH awarded a $23 million grant to the university to repurpose hypertension drug isradipine to treat Parkinson's disease. MJFF said that in September, Northwestern and the Parkinson Study Group plan to begin a...
08:00 , Dec 3, 2007 |  BC Week In Review  |  Company News

Reliant, GlaxoSmithKline deal

GSK will acquire Reliant for $1.7 billion in cash. The acquisition gives GSK U.S. rights to Lovaza omega 3 acid ethyl esters, which is marketed for use as an adjunct to diet to treat hypertriglyceridemia....
08:00 , Dec 3, 2007 |  BioCentury  |  Finance

Ebb & Flow II

The $1.7 billion in cash that GlaxoSmithKline (LSE:GSK; GSK) paid for specialty pharma company Reliant is not providing a hefty return for some of the latter's long-term investors. Alkermes (ALKS), which owns 12.9% of Reliant,...
00:27 , Nov 22, 2007 |  BC Extra  |  Top Story

GSK acquiring Reliant for $1.7B

GlaxoSmithKline (LSE:GSK; GSK) said it will acquire cardiovascular company Reliant (Liberty Corner, N.J.) for $1.7 billion in cash. The acquisition gives GSK U.S. rights to Lovaza , which is marketed for use as an adjunct...
07:00 , Oct 29, 2007 |  BioCentury  |  Finance

Ebb & Flow

Biogen Idec (BIIB) was off last week on slowing sales of Avonex interferon beta-1a, eroding $3.50 to $76.72 for the week. On the company's conference call, President and CEO James Mullen said 3Q07 sales of...
01:48 , Oct 26, 2007 |  BC Extra  |  Financial News

Reliant amends IPO

Cardiovascular company Reliant (Liberty Corner, N.J.) amended its IPO and hopes to sell 10 million shares at $25-$27 in an offering underwritten by Goldman Sachs; Merrill Lynch; JPMorgan; Banc of America Securities; and Lazard. A...
00:41 , Aug 11, 2007 |  BC Extra  |  Financial News

Reliant refiles for IPO

Cardiovascular company Reliant (Liberty Corner, N.J.) refiled for an IPO and hopes to raise up to $400 million in an offering underwritten by Goldman Sachs; Merrill Lynch; JPMorgan; Bank of America Securities; and Lazard. The...
03:25 , Nov 18, 2005 |  BC Extra  |  Financial News

Reliant pulls IPO

Cardiovascular company Reliant (Liberty Corner, N.J.) withdrew its proposed IPO, citing market conditions. In May, Reliant filed to raise up to $300 million through Goldman Sachs; Banc of America Securities; Deutsche Bank; JPMorgan; William Blair;...